Glaukos (NYSE:GKOS) Price Target Increased to $112.00 by Analysts at BTIG Research

Glaukos (NYSE:GKOS - Get Free Report) had its target price lifted by equities research analysts at BTIG Research from $107.00 to $112.00 in a research report issued on Thursday, Benzinga reports. The firm presently has a "buy" rating on the medical instruments supplier's stock. BTIG Research's price objective would indicate a potential upside of 6.53% from the company's current price.

Other research analysts also recently issued research reports about the company. Needham & Company LLC upped their price objective on Glaukos from $108.00 to $113.00 and gave the company a "buy" rating in a research note on Thursday. Wells Fargo & Company upped their price objective on Glaukos from $103.00 to $110.00 and gave the company an "overweight" rating in a research note on Thursday. JPMorgan Chase & Co. upped their price objective on Glaukos from $108.00 to $110.00 and gave the company an "overweight" rating in a research note on Thursday. Truist Financial reaffirmed a "buy" rating and issued a $125.00 price objective (up previously from $120.00) on shares of Glaukos in a research note on Thursday. Finally, StockNews.com downgraded Glaukos from a "hold" rating to a "sell" rating in a research note on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, Glaukos has an average rating of "Moderate Buy" and an average target price of $107.00.

Glaukos Price Performance

NYSE GKOS traded up $6.22 during trading on Thursday, hitting $105.13. 849,202 shares of the company's stock were exchanged, compared to its average volume of 655,382. The company has a current ratio of 5.34, a quick ratio of 4.78 and a debt-to-equity ratio of 0.77. The company has a market cap of $5.28 billion, a PE ratio of -37.82 and a beta of 1.08. Glaukos has a fifty-two week low of $45.47 and a fifty-two week high of $108.22. The stock's 50 day moving average price is $92.99 and its two-hundred day moving average price is $82.59.

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.12). The business had revenue of $85.60 million for the quarter, compared to analyst estimates of $79.60 million. Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The firm's revenue was up 15.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.59) EPS. Research analysts expect that Glaukos will post -2.16 EPS for the current year.

Insiders Place Their Bets

In other Glaukos news, CFO Alex R. Thurman sold 1,372 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $100.54, for a total transaction of $137,940.88. Following the transaction, the chief financial officer now directly owns 52,532 shares in the company, valued at approximately $5,281,567.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Glaukos news, CFO Alex R. Thurman sold 1,372 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $100.54, for a total transaction of $137,940.88. Following the transaction, the chief financial officer now directly owns 52,532 shares in the company, valued at approximately $5,281,567.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mark J. Foley sold 4,560 shares of the stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $92.87, for a total value of $423,487.20. Following the transaction, the director now owns 33,220 shares in the company, valued at $3,085,141.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 232,881 shares of company stock worth $21,965,491. Corporate insiders own 6.40% of the company's stock.

Hedge Funds Weigh In On Glaukos

Large investors have recently modified their holdings of the company. National Bank of Canada FI bought a new position in shares of Glaukos in the 4th quarter worth $46,000. GAMMA Investing LLC bought a new position in shares of Glaukos in the 4th quarter worth $55,000. Quadrant Capital Group LLC lifted its holdings in shares of Glaukos by 54.8% in the 4th quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier's stock worth $74,000 after purchasing an additional 329 shares in the last quarter. Caldwell Sutter Capital Inc. lifted its holdings in shares of Glaukos by 5,860.0% in the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier's stock worth $140,000 after purchasing an additional 1,465 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Glaukos by 17.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier's stock worth $137,000 after purchasing an additional 270 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.